BIOA

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

Roth Capital initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $36.00

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–4, 2026): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, are scheduled to participate in a fireside chat on Thursday, June 4 at 3:45–4:15 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. • Gol

Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun

SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)

Equity Insider News CommentaryIssued on behalf of Avaí Bio, Inc.Joint venture with Austrianova advances the production of cells that produce the longevity protein α-Klotho from encapsulated cells; latest data to be presented at the Second Annual Klotho ConferenceNEW YORK, May 14, 2026 /CNW/ -- Longevity and anti-aging therapeutics have moved decisively from frontier science to organized commercial development through the first half of 2026. Industry data show approximately $3.74 billion of disclosed longevity-biotech financing in Q1 2026 across 49 deals — a 56% increase in capital deployed over Q1 2025 — and the broader longevity biotech market has been forecast to reach approximately US$29.

BTIG Research initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $40.00

8-K - BioAge Labs, Inc. (0001709941) (Filer)

10-Q - BioAge Labs, Inc. (0001709941) (Filer)

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept trial of BGE-102 in cardiovascular risk planned to initiate in mid-2026, with data anticipated by end of year Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema (DME) planned to initiate in mid-2026, with data anticipated in mid-2027 Completed upsized follow-on public offering of $132.3 million EMERYVILLE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or, "the Company"), a clinical-stage biopharmaceutical company developing

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease Four leading academic and clinical experts will join BioAge management for presentations, followed by a live question-and-answer session EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that it will host an R&D Day webcast on Friday, May 8, 2026

4 - BioAge Labs, Inc. (0001709941) (Issuer)

DEFA14A - BioAge Labs, Inc. (0001709941) (Filer)

DEF 14A - BioAge Labs, Inc. (0001709941) (Filer)

120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to initiate mid-2026, with results anticipated by end of year Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) planned to initiate mid-2026, with results anticipated mid-2027 BioAge to host conference call and webcast today at 8:00 AM ET to discuss BGE-102 results EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinical-stage biopharm

EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference taking place April 13–16, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, April 16 from 3:00 PM to 3:30 PM EDT. Kristen Fortney, Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, will participate in one-on-one meetings. To access the live webcast of the p

4 - BioAge Labs, Inc. (0001709941) (Issuer)

144 - BioAge Labs, Inc. (0001709941) (Subject)

Needham initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $50.00